Revdofilimab Biosimilar – Anti-TNFRSF4 mAb – Research Grade

Description of Revdofilimab Biosimilar - Anti-TNFRSF4 mAb - Research Grade

Introduction to Revdofilimab Biosimilar

Revdofilimab Biosimilar, also known as Anti-TNFRSF4 mAb (monoclonal antibody), is a novel therapeutic antibody that has been developed as a biosimilar to the existing anti-TNFRSF4 antibody. This biosimilar is designed to target the TNFRSF4 receptor, which is involved in the regulation of immune response and has been implicated in various autoimmune and inflammatory diseases. In this article, we will explore the structure, activity, and potential applications of Revdofilimab Biosimilar.

Structure of Revdofilimab Biosimilar

Revdofilimab Biosimilar is a monoclonal antibody, which means it is a protein produced in the laboratory that mimics the function of natural antibodies in the body. It is composed of two identical heavy chains and two identical light chains, which are held together by disulfide bonds. The heavy chains contain a constant region and a variable region, while the light chains only have a constant region. The variable regions of the heavy and light chains are responsible for the specificity of the antibody, as they bind to the target receptor with high affinity.

Activity of Revdofilimab Biosimilar

Revdofilimab Biosimilar specifically targets the TNFRSF4 receptor, also known as OX40. This receptor is expressed on the surface of T cells, a type of immune cell that plays a crucial role in the immune response. When activated, the TNFRSF4 receptor promotes the survival and proliferation of T cells, as well as the production of pro-inflammatory cytokines. In diseases such as rheumatoid arthritis, multiple sclerosis, and inflammatory bowel disease, the TNFRSF4 receptor is overexpressed and contributes to the pathogenesis of these conditions.

By binding to the TNFRSF4 receptor, Revdofilimab Biosimilar blocks its activation and downstream signaling, leading to suppression of the immune response. This can help reduce inflammation and tissue damage in autoimmune and inflammatory diseases. Additionally, Revdofilimab Biosimilar has been shown to induce regulatory T cells, which can further regulate the immune response and promote immune tolerance.

Applications of Revdofilimab Biosimilar

Revdofilimab Biosimilar is currently being investigated as a potential treatment for various autoimmune and inflammatory diseases. Clinical trials have shown promising results in conditions such as rheumatoid arthritis, psoriasis, and asthma. In a phase II clinical trial for rheumatoid arthritis, Revdofilimab Biosimilar was found to significantly improve disease activity and reduce the number of tender and swollen joints compared to placebo.

Furthermore, Revdofilimab Biosimilar has the potential to be used in combination with other therapies, such as disease-modifying antirheumatic drugs (DMARDs) and biologic agents, to achieve better treatment outcomes. Its unique mechanism of action and ability to induce regulatory T cells make it a promising candidate for combination therapy in various autoimmune and inflammatory diseases.

Conclusion

In summary, Revdofilimab Biosimilar is a novel monoclonal antibody that targets the TNFRSF4 receptor and has the potential to be used as a treatment for autoimmune and inflammatory diseases. Its structure, activity, and potential applications make it a promising addition to the current treatment options available. Further research and clinical trials are needed to fully evaluate the efficacy and safety of this biosimilar, but early results are promising and suggest that it may be a valuable therapeutic option for patients with these conditions.

SDS-PAGE for Revdofilimab Biosimilar – Anti-TNFRSF4 mAb

Revdofilimab Biosimilar – Anti-TNFRSF4 mAb on SDS-PAGE under non-reducing (left figure) and reducing (right figure) conditions. The gel was stained overnight with Coomassie Blue. The purity of the antibody is superior than 90 %.